Apollon Fortifies Global IP Leadership in Metabolic Health with New U.S. Patents for Raman Spectroscopy-Based Non-Invasive CGM
Cambridge, MA – Apollon, a deep-tech medical device innovator, today announced the further strengthening of its intellectual property portfolio with the granting of two foundational patents by the United States Patent and Trademark Office (USPTO): US 12,502,105 (issued Dec 23, 2025) and US 12,507,917 (issued Dec 30, 2025).
These patents secure Apollon’s proprietary apparatus and methodology for a wearable, needle-free continuous glucose monitor (CGM). To date, Apollon has successfully secured 14 issued patents, received Notices of Allowance for 2 additional patents, and has 26 more applications pending. Notably, the company maintains a 100% success rate with zero rejections to date, and a comprehensive Freedom to Operate (FTO) analysis has confirmed no conflicting IP in the space.
Breaking the "ML-Dependency" Trap
While many non-invasive attempts rely on indirect PPG signals and heavy machine learning (ML) "guessing," Apollon’s patented Moglu® technology utilizes three precise wavelengths via Raman spectroscopy to capture the actual molecular fingerprints of glucose.
Physical Signal Superiority: The patents cover a unique hardware architecture that isolates high-fidelity glucose signatures directly from physical signals. In Apollon’s system, ML is not used as a rescue for weak data, but as a powerful enhancer for already high-quality physical measurements.
Clinical Validation Roadmap: Apollon is set to conduct performance validation on human subjects using the Moglu® prototype within the first half of this year. Furthermore, the company maintains a strategic R&D collaboration with the MIT Laser Biomedical Research Center, focusing on performance testing and system optimization to ensure world-class reliability.
Strategic IP Fortress
"Our patent strategy is not just about quantity, but about the quality and integrity of the protection," said the Apollon team. "With zero rejections and a clear FTO status, we have built a formidable moat around our Raman-based sensing physics. We are building what the market actually needs: a clinically validated, needle-free solution that just works."
With the upcoming human performance tests in the first half of the year, Apollon is poised to solidify its position as a game-changer in the non-invasive metabolic health market.
About Apollon
Apollon is a medtech company dedicated to redefining glucose monitoring through the power of Raman spectroscopy. Headquartered in Seoul with strategic clinical ties in Boston, Apollon is building the future of non-invasive metabolic health.
